Enliven: Clinical Cardiology and Research

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: an Emerging Chapter in the Field of Clinical Lipidology
General Information

Research Report

Constantine E. Kosmas, MD, PhD1, and Eddy DeJesus, MD2


1Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY


2Cardiology Unlimited, PC


Corresponding author

Constantine E. Kosmas, MD, PhD, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai,168-24 Powells Cove Blvd. Beechhurst, NY, 11357, E-mail: cekosmas1@gmail.com

 

Received Date: 04th May 2015

Accepted Date: 04th May 2015

Published Date: 10th May 2015


Citation

Kosmas CE, and DeJesus E (2015) Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: an Emerging Chapter in the Field of Clinical Lipidology. Enliven: Clin Cardiol Res 2(1): e1.

Copyright

@ 2015 Dr. Constantine E. Kosmas. This is an Open Access article published and distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

The role of low-density lipoprotein cholesterol (LDL-C) in the pathophysiology of atherosclerosis is well recognized, and statin therapy represents the standard of care for LDL-C lowering and reduction of cardiovascular risk. However, many patients fail to achieve LDL-C goals, while others are intolerant to statins due to side effects. Unfortunately, until recently, the efficacy of other non-statin LDL-C-lowering agents was limited, achieving an LDL-C reduction of no more than 20%. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors represent a new class of LDL-lowering agents, producing large reductions in LDL-C. The present review aims to provide the current clinical and scientific data pertaining to this promising new class of LDL-C-lowering agents.

 

Keywords

Hypercholesterolemia; LDL receptors; Statins; PCSK9 inhibitors

 

The role of low-density lipoprotein cholesterol (LDL-C) in the pathophysiology of atherosclerosis is well recognized, and statin therapy represents the standard of care for LDL-C lowering and reduction of cardiovascular risk. However, many patients fail to achieve LDL-C goals, while others are intolerant to statins due to side effects. Unfortunately, until recently, the efficacy of other non-statin LDL-C-lowering drugs was limited, achieving an LDL-C reduction of no more than 20%. Thus, extensive research is being carried out to identify new LDL-C-lowering agents with an acceptable side effect profile, which, used alone or in combination with statins, would improve our ability to achieve LDL-C goals and reduce cardiovascular risk [1].

It has been more than a decade since Seidah et al. [2] identified the ninth member of the proprotein convertase family, PCSK9. Proprotein Convertase Subtilisin/Kexin Type 9 is a serine protease, mainly expressed in the liver but also in the intestine and kidneys, located in the human chromosome 1p32.3 that encodes a 692 amino acid inactive glycoprotein [3]. It promotes the degradation of LDL receptors (LDLR) by reducing their recycling and targeting the receptors for lysosomal destruction, thus decreasing the rate of removal of LDL-C from the circulation. This was demonstrated in vitro and in mouse models and inferred by genetic studies in patients with PCSK9 mutations [4-6].

Abifadel, et al. [7] first reported that a specific heterozygous PCSK9 missense mutation caused autosomal dominant hypercholesterolemia. Because loss of a single allele is usually functionally inconsequential, the authors immediately raised the possibility that PCSK9 missense mutations might increase plasma cholesterol levels via a gain-of-function mechanism. This has actually been shown in several clinical and experimental studies [7-10].

Since PCSK9 is a key regulator for LDLR activity, and given the fact that statins upregulate PCSK9 with consequent attenuation of their LDL-C-lowering effect [11], its inhibition seems an attractive target for the treatment of hypercholesterolemia. So far, several therapeutic strategies have been developed in order to reduce circulating PCSK9; however, monoclonal antibodies have emerged as the new class of drugs that very effectively lower LDL-C levels [12].

To date, the humanized monoclonal antibodies designated AMG 145 or Evolocumab, REGN727/SAR236553 or Alirocumab, and RN316 or Bococizumab have mostly been studied in the last few years.

In two studies named Open-Label Study of Long-Term Evaluation against LDL Cholesterol 1 (OSLER-1) and 2 (OSLER-2), a randomized, open-label design was used in a total of 4,465 patients with various degrees of cardiovascular risk. Evolocumab, administered subcutaneously at a dose of 140 mg every 2 weeks or 420 mg monthly, was added to standard therapy and compared with standard therapy alone over a period of approximately 1 year [13].

The results of these two studies, which were analyzed and reported together, showed that after 12 weeks evolocumab, as compared with standard therapy, reduced the LDL cholesterol level by 61% (95% confidence interval [CI], 59 to 63; P<0.001), and this reduction remained consistent over time. Evolocumab raised levels of HDL cholesterol and apolipoprotein A1 by 7.0% and 4.2%, respectively (P<0.001 for both comparisons) [13].

The adverse events included some non-specific ones, such as arthralgias, headache, limb pain and fatigue, although some neurocognitive adverse events were found to be more frequent in the evolocumab group compared to the standard-therapy group. The rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003) [13].

Long-Term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM), was a double-blind, randomized, controlled trial of Alirocumab (150 mg SQ every 2 weeks) versus placebo for 78 weeks in 2,341 patients at high risk for cardiovascular events, who were already receiving the maximum tolerated doses of statins [14].

In the ODYSSEY LONG TERM trial, the PCSK9 inhibitor alirocumab, as compared with placebo, reduced LDL cholesterol levels in high-risk patients by an additional 62% when added to statin therapy at the maximum tolerated dose, with or without other lipid-lowering therapy. The effect was consistent over a period of 78 weeks of therapy. The efficacy of alirocumab was similar across various subgroups, including those defined according to the presence or absence of heterozygous familial hypercholesterolemia. In addition, there was a reduction of 26% versus placebo in the levels of lipoprotein (a) [14].

With respect to specific adverse events, the alirocumab group had higher rates than the placebo group of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P= 0.02) [14]
.

In another 24 week, multicenter, randomized, double blind, placebo-controlled, parallel group, dose ranging phase 2b study (NCT01592240), bococizumab significantly reduced LDL-C levels across all doses [15].The primary end point was the absolute change in LDL-C levels from baseline to week 12 after placebo or bococizumab administration. Of the 354 subjects randomized, 351 received treatment (placebo [n= 100] or bococizumab [n = 251]). The most efficacious bococizumab doses were 150 mg Q14 days and 300 mg Q28 days. Compared with placebo, bococizumab 150 mg Q14 days reduced LDL-C at week 12 by 53.4 mg/dl and bococizumab 300 mg Q28 days reduced LDL-C by 44.9 mg/dl (inclusive of the protocol-directed dose reductions for LDL-C readings ? 25 mg/dl in 32.5% and 34.2% of subjects at week 10 or 8, respectively) [15].

Adverse events were similar across placebo and bococizumab groups. Few subjects (n = 7; 2%) discontinued treatment because of treatment-related adverse events. In conclusion, bococizumab significantly reduced LDL-C across all doses despite dose reductions in approximately 35% of the subjects [15].


References

  1. Kosmas CE, Frishman WH (2014) New and Emerging LDL Cholesterol-Lowering Drugs. Am J Ther.

  2. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A100: 928-933.

  3. Seidah NG, Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov11: 367-368.

  4. Lambert G, Charlton F, Rye KA, Piper DE (2009) Molecular basis of PCSK9 function. Atherosclerosis 203: 1-7.

  5. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, et al. (2007) Secreted PCSK9 down regulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 48: 1488-1498.

  6. Weinreich M, Frishman WH ( 2014) Antihyperlipidemic therapies targeting PCSK9. Cardiol Rev 22: 140-146.

  7. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.

  8. Horton JD, Cohen JC, Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50: 172-177.

  9. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, et al. ( 2005) Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25: 2654-2560.

  10. Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, et al. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 15: 1551-1558.

  11. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, et al. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24: 1454-1459.

  12. Stein EA, Raal FJ (2014) New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am 43: 1007-1033.

  13. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, et al. (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500-1509.

  14. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, et al. (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med 372: 1489-1499.

  15. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, et al. (2015) Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115: 1212-1221.

  16. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. (2015) Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med.

Curriculum Vitae

 

Constantine E. Kosmas, M.D., Ph.D., Facc, Facp


ASSISTANT CLINICAL PROFESSOR OF MEDICINE (CARDIOLOGY)
DIRECTOR OF LIPID CLINIC, CARDIOLOGY UNLIMITED, P.C.
Diplomate, Certification Board of Nuclear Cardiology
Diplomate, American Board of Clinical Lipidology

Contact Information
CONSTANTINE E. KOSMAS, M.D., Ph.D.
168-24 POWELLS COVE BOULEVARD
BEECHHURST, NEW YORK 11357
TELEPHONE: (646) 734-7969
E-mail: cekosmas1@gmail.com

 

Education:

1977 - 1983    University of Athens Medical School, Athens, Greece. (Premedical education is included in the six-year medical school). Graduated with ?Excellent? with an M.D. degree.

1971 - 1977    Experimental High School of the University of Athens, Athens, Greece. This school was established for students who had the potential for academic excellence. Graduated with ?Excellent?.

 

Fellowship:

7/1992 - 6/1995    Episcopal Hospital,Philadelphia, Pennsylvania. Fellow in the three-year Cardiology program.

 

Residencies:

7/1989 - 6/1992     St. John?s Episcopal Hospital, SouthShore, Far Rockaway, New York. Resident in the three-year Internal Medicine program.

6/1987 - 5/1989      AlexandraUniversityHospital,Athens, Greece. Resident in the Internal Medicine program. (Interrupted in order to commence training in the USA).

8/1984 - 3/1985      251 General Air Force Hospital, Athens, Greece. Intern in Internal Medicine during military service.

 

Doctoral Thesis:

1992     Doctorate in Medicine (Ph. D.) granted with ?Excellent? by the University of Athens Medical School, Athens, Greece:
Kosmas CE: Substitution of the left and right ventricles by counter pulsation pumps during ventricular fibrillation. Mechanism of the hemodynamic effect of the right ventricular pump.
Doctoral Thesis. From the Department of Clinical Therapeutics, University of Athens, Athens, Greece, June 1992. [62 pages, 113 references. In Greek with English summary]

 

Other Experience:

5/1986 - 1/1987      ?Health Mansions? Clinic, Athens, Greece. Internal assistant in Medicine, temporarily before starting residency.

5/1985 - 5/1986      Agrarian Clinic of Mavrikion, Mavrikion, Ahaia, Greece. One-year mandatory general medical practice in rural Greece.

 

Military Service:

10/1983 - 5/1985    Military service in the Greek Air Force. Practiced medicine for most of period of military service.

 

Employment History:

9/2014 ? Present    Cardiology Unlimited, P.C.
                             5030 Broadway, Suite 649
                             New York, NY 10034

3/2011 ? 8/2014    Mount Sinai Medical Center
                           One Gustave L. Levy Place
                           New York, NY 10029

7/2000 ? 1/2011      Cardiovascular Associates of New York
                             44-01 Francis Lewis Boulevard
                             Bayside, NY 11361

7/1995 - 6/2000      Vidya S. Banka, M.D. & Assoc., P.C.
                             Garfield Duncan Building, Suite 2B
                             301 S. 8th Street
                             Philadelphia, PA 19106

 

Faculty Appointments:

3/2011                   Assistant Professor of Medicine (Cardiology)
                             Department of Medicine, Division of Cardiology
                             Mount Sinai School of Medicine
                             New York, New York.

1/2001                   Clinical Assistant Professor of Medicine (Cardiology)
                             WeillMedicalCollege of CornellUniversity,
                             New York, New York.

7/1999                   Clinical Assistant Professor of Medicine (Cardiology)
                             Department of Medicine,
                             MedicalSchool of the University of Pennsylvania,
                             Philadelphia, Pennsylvania.

7/1997                   Clinical Associate
                             Department of Medicine,
                             MedicalSchool of the University of Pennsylvania,
                             Philadelphia, Pennsylvania.

 

Hospital Appointments:

5/2011 - Present                   Cardiology Attending
                                           Mount Sinai Hospital of Queens, Astoria, New York.

3/2011 - Present                   Cardiology Attending
                                           Mount Sinai Hospital, New York, New York.

5/2010 ? 1/2011                   Cardiology Attending
                                           North Shore University Hospital, Manhasset, New York.

7/2008 ? 1/2011                   Cardiology Attending
                                           Lenox Hill Hospital, New York, New York.

 

  • Direct patient care and clinical supervision of the Cardiology fellows, medical residents and Physician Assistants.

7/2000 ? 1/2011                   Cardiology Attending
                                           New York Hospital Queens, Flushing, New York.

 

  • Direct patient care and clinical supervision of the Cardiology fellows (7/2004-6/2008), medical residents and medical students.


  • Teaching of the Cardiology fellows (7/2004-6/2008), medical residents (7/2000-6/2008), as well as medical students from Weill Medical College of Cornell University (7/2000-6/2008), during work rounds and at bedside in the Coronary Care Unit and Cardiology wards, as well as with numerous teaching sessions and lectures on a daily basis.


  • Interpretation of approximately 1000 electrocardiograms per year, including exercise electrocardiograms and Holter recordings (7/2000-6/2008).


  • Interpretation of approximately 1000 cardiac nuclear studies per year. [Cardiovascular Associates of New York, P.C.: First Floor, Nuclear Stress Room, 44-01 Francis Lewis Blvd., Bayside, New York 11361 and Cardiovascular Associates of New York, P.C.:23-18 31 Street, Astoria, New York 11105 (2003-2011)-Radiation Safety Officer for this facility] .


  • Performance of approximately 50 cardiac catheterizations per year (2000-2001).


Hospital Appointments (Cont.):

1/2002 ? 6/2003                   Acting Director, Coronary Care Unit
                                           New York Hospital Queens, Flushing, New York.

 

  • Clinical and administrative supervisory responsibilities for the development and optimization of clinical curricula for the comprehensive training and teaching of the medical residents in the Coronary Care Unit.


  • Clinical and administrative supervisory responsibilities for the development and optimization of clinical protocols for optimal, evidence-based management of the patients admitted to the Coronary Care Unit.


  • Clinical and administrative supervisory responsibilities for the optimal operation of the Coronary Care Unit.


7/1996 ? 6/2000                   Cardiology Attending
                                           Pennsylvania Hospital, Philadelphia, Pennsylvania.

 

  • Direct patient care and clinical supervision of the medical residents and medical students.


  • Teaching of the medical residents, as well as medical students from Thomas Jefferson University and University of Pennsylvania, during work rounds and at bedsidein the Coronary Care Unit and Cardiology wards, as well as with numerous teaching sessions and lectures on a daily basis.


  • Interpretation of approximately 3000 electrocardiograms per year (including exercise electrocardiograms and Holter recordings).


  • Interpretation of approximately 300 echocardiographic studies per year.


  • Performance of approximately 150 cardiac catheterizations per year (including intra-aortic balloon pump insertions).


Hospital Appointments (Cont.):

8/1995 - 6/2000                   Cardiology Attending
                                           Episcopal Hospital, Philadelphia, Pennsylvania.

 

  • Direct patient care and clinical supervision of the Cardiology fellows, medical residents and medical students.


  • Training of the Cardiology fellows in the Cardiac Catheterization Laboratories, Echocardiography Laboratory and the Nuclear Cardiology Laboratory on a daily basis.


  • Teaching of the Cardiology fellows, medical residents, as well as medical students from Medical College of Pennsylvania, Thomas Jefferson University and Temple University, during work rounds and at bedsidein the Coronary Care Unit and Cardiology wards, as well as in the Cardiology Clinic and with numerous teaching sessions and lectures on a daily basis.


  • Interpretation of approximately 5000 electrocardiograms per year (including exercise electrocardiograms and Holter recordings).


  • Interpretation of approximately 1000 echocardiographic studies per year.


  • Interpretation of approximately 2000 cardiac nuclear studies per year.


  • Performance of approximately 200 cardiac catheterizations per year (including pulmonary angiograms and intra-aortic balloon pump insertions).


8/1995 - 9/1999                   Director, Clinical Services
                                          Episcopal Hospital, Philadelphia, Pennsylvania.

 

  • Clinical and administrative supervisory responsibilities for the development and optimization of clinical curricula for the comprehensive training and teaching of the Cardiology fellows.


  • Clinical and administrative supervisory responsibilities for the optimal operation of the Cardiology Clinics.


8/1995 - 9/1999                   Associate Director, Nuclear Cardiology
                                          Episcopal Hospital, Philadelphia, Pennsylvania.

 

  • Clinical and administrative supervisory responsibilities for the comprehensive training and teaching of the Cardiology fellows in the field of Nuclear Cardiology.


  • Clinical and administrative supervisory responsibilities for the optimal operation of the Nuclear Cardiology Laboratory.


Hospital Committees:

1/2002 ? 6/2008                   Pharmacy and Therapeutics Committee
                                           New York Hospital Queens, Flushing, New York.

1/2002 ? 6/2003                   Critical Care Committee
                                           New York Hospital Queens, Flushing, New York.

 

Practice Appointments:

9/2014 ? Present                   Director of Lipid Clinic, Cardiology Unlimited, P.C.
                                           629 West 185th Street, 2nd Floor
                                           New York, NY 10033

3/2011 ? 8/2014                   Medical Director, Mount Sinai Advanced Cardiovascular Group
                                           30-74 31st Street, 5th Floor
                                           Astoria, NY 11102

 

Teaching Assignments:

3/2011 ? 8/2014                   Cardiology Teaching Attending in 7 Center Cardiac Telemetry Floor
                                           Mount Sinai Hospital, New York, New York

 

  • Discussing with medical residents and medical students the presentation and clinical course of patients admitted to the Cardiac Telemetry Floor and making decisions regarding their clinical management.


3/2011 ? 8/2014                   Cardiology Teaching Attending in Coronary Care Unit
                                           Mount Sinai Hospital, New York, New York.

 

  • Discussing with Cardiology fellows and medical residents the presentation, clinical course and management of patients admitted to the Coronary Care Unit.


7/2000 ? 6/2008                   Cardiology Teaching Attending in Coronary Care Unit
                                           New York Hospital Queens, Flushing, New York.

 

  • Discussing with Cardiology fellows (7/2004-6/2008)and medical residents the presentation, clinical course and management of patients admitted to the Coronary Care Unit.


7/2000 ? 6/2008                   Cardiology Teaching Attending in 2N Cardiac Telemetry Floor
                                           New York Hospital Queens, Flushing, New York.

 

  • Discussing with Cardiology fellows (7/2004-6/2008)and medical residents the presentation and clinical course of patients admitted to the Cardiac Telemetry Floor and making decisions regarding their clinical management.


Teaching Assignments (Cont.):

7/2000 ? 6/2008                   Cardiology Teaching Attending - BMA Consult Services
                                           New York Hospital Queens, Flushing, New York.

 

  • Discussing a large spectrum of cardiac clinical didactic cases with Cardiology fellows (7/2004-6/2008)and medical residents and teaching them how to perform a comprehensive cardiac consultation.


11/2000                 Preceptor of Third-Year Clerkship in Internal Medicine for medical students from                                 WeillMedicalCollege of Cornell University
                                New York Hospital Queens, Flushing, New York.

 

  • Discussing clinical cases and teaching third-year medical students how to obtain a comprehensive history, perform a thorough physical exam, optimally assess the pertinent laboratory data and make an appropriate differential diagnosis.


7/1996 - 6/2000                   Cardiology Teaching Attending in Coronary Care Unit
                                           Pennsylvania Hospital, Philadelphia, Pennsylvania.

 

  • Discussing with medical residents, as well as medical students from ThomasJeffersonUniversity and the University of Pennsylvania, the presentation, clinical course and management of patients admitted to the Coronary Care Unit.


7/1996 - 6/2000                   Cardiology Teaching Attending - Consult and Emergency Room Service
                                           Pennsylvania Hospital, Philadelphia, Pennsylvania.

 

  • Discussing a large spectrum of cardiac clinical didactic cases, including the immediate management of patients in the Emergency Room, with medical residents, as well as medical students from Thomas Jefferson University and the University of Pennsylvania, and teaching them how to perform a comprehensive cardiac consultation.


8/1994 - 7/1996                   Teaching Attending in Internal Medicine
                                           Episcopal Hospital, Philadelphia, Pennsylvania.

 

  • Discussing with medical residents, as well as medical students from the MedicalCollege of Pennsylvania, the presentation and clinical course of patients admitted to the General Medical Floors and making decisions regarding their clinical management.


8/1994 - 6/1995                   Clinical Instructor in Cardiac Diagnostics
                                           Episcopal Hospital, School of Perfusion Science, Philadelphia, Pennsylvania.

 

  • Giving series of lectures within the Cardiac Diagnostic curricula to students from Episcopal Hospital School of Perfusion Science. The topics of the lectures were: ?Coronary Artery Disease?, ?Cardiac Arrhythmias and Pacing? and ?Cardiomyopathies?.


Consulting Positions:

Scientific Advisor at the General Hospital of Piraeus ?Hippocrates?, Piraeus, Greece.

 

Specialty Certifications:

2007                   Board Certification in Clinical Lipidology in the United States of America.

2002                 Board Certification in Nuclear Cardiology in the United States of America. Recertified                           for the period 2013-2023.

1996                   Board Certification in Cardiovascular Disease in Greece.

1995       Board Certification in Cardiovascular Disease in the United States of America.                         Recertified for the period 2005-2015 and for the period 2015-2025.

1993                   Board Certification in Internal Medicine in Greece.

1992                   Board Certification in Internal Medicine in the United States of America.

 

Medical Licenses:

1999                   Fully registered with the General Medical Council in the United Kingdom as a specialist in                           General (Internal) Medicine and Cardiology.
                          (Registration #: 4609355)

1995                   Licensed to practice Medicine and Surgery in the State of New York.
                          (License #: 198677)

1992                   Licensed to practice Medicine in the Commonwealth of Pennsylvania.
                          (License #: MD-046784-L)

1983                   Licensed to practice Medicine in Athens, Greece.

 

Other Licenses and Certifications:

 

2001

Certification for successful completion of the TIKOSYN Education Program by the TIKOSYN Program Administration. This certification qualifies the ecipient physician to prescribe the anti-arrhythmic drug TIKOSYN? (dofetilide)

 

2001

Radioactive Materials License by the City of New York, Department of Health, Bureau of Radiological Health authorizing the use of radioactive material for cardiovascular studies.
(License #: 91-3134-01)

 

2000

Certification for successful completion of the course ?Clinical Applications in Nuclear Medicine?, including training in the Nuclear Medicine software packages e.soft and Basic ICON, by Siemens Medical Systems, Inc.,
(Reference #: ILZ0191001)

 

2000

Certification for successful completion of an approved course in Infection Control by the New York State Department of Health and the New York State Education Department.

 

1995

Materials License by the U. S. Nuclear Regulatory Commission authorizing the use of radioactive material for cardiovascular clinical procedures.
(License #: 37-03420-01)

 

1995

Radioactive Material License by the Commonwealth of Pennsylvania, Department of Environmental Protection, Bureau of Radiation Protection authorizing the use of radioactive material for cardiovascular studies.
(License #: PA-0123)

 

1995

Certification for successful completion of the 200-hour Physician Training Program in Basic Radioisotope Handling conducted in accordance with the requirements of the U. S. Nuclear Regulatory Commission (10 CFR 35) by Health Physics Services, Inc.

Pharmaceutical Speaker Bureaus and Advisory Panels:

2015 - Present

Member of the Dyslipidemia Speaker Bureau and the Heart Failure Speaker Bureau of Amgen, Inc.

 

2015 - Present

Consultant of Sanofi US

 

2009 - 2010

Member of the Speaker Bureau of Lilly USA, LLC

 

2008 - 2011

Member of the Speaker Bureau of GlaxoSmithKline

 

2007

Member of the Speaker Bureau of King Pharmaceuticals, Inc.

 

2006 - 2011

Member of the Speaker Bureau of Abbott Laboratories

 

2006 - 2008

Member of the Speaker Bureau of Novartis Pharmaceuticals Corporation

 

2005 - 2011

Member of the Speaker Bureau of BoehringerIngelheim Pharmaceuticals, Inc.

 

2004 - 2011

Member of the Speaker Bureau of Forest Pharmaceuticals, Inc.

 

2004

Member of the Speaker Bureau of Millennium Pharmaceuticals, Inc.

 

2004 - 2011

Member of the Speaker Bureau of Daiichi Sankyo, Inc.

 

2003 - 2008

Member of the Lecture Bureau of AstraZeneca LP

 

2001 - 2002

Member of the Speaker Bureau of Merck & Co., Inc.

 

1996 - 2009

Member of the Speaker Bureau of Pfizer, Inc.

 

10/5/2007

Cardiology Consultant in the Abbott Laboratories Cardiology Advisory Board Meetingentitled: ?Addressing Triglycerides and HDL-C Beyond Statin Monotherapy to Reduce CVD Risk? [New York]

 

6/12/2003

Member of the GlaxoSmithKline Carvedilol Regional Post-MI Advisory Panel, establishing the role of Carvedilol in high-risk patients with LVD [New York]

 

11/28/2000

Member of the Unimed Pharmaceuticals, Inc. Consultant Advisory Panel to discuss matters relating to Unimed?s drug Teveten? (Eprosartanmesylate) [New York]

 

5/28/1997

Member of the SmithKline Beecham Pharmaceuticals Regional Advisory Board to discuss pertinent issues relating to SmithKline Beecham?s drug Coreg? (Carvedilol) [Pennsylvania]

 

Honors and Awards:

2001 - 2004

Physician?s Recognition Award from the American Medical Association for fulfilling the requirements for this award in Continuing Medical Education.

 

2001

Certificate of Appreciation from the New York Hospital Queens in recognition of the recipient?s efforts in support of the Outreach Programs presented to the community by New York Hospital Queens.

 

1998 - 2001

Award of Excellence from the Pennsylvania Medical Society for completion of 150 hours of Continuing Medical Education within the last three years that fulfills the highest standards of continuing education set by the members of the Society.

 

1995 - 1998

Physician?s Recognition Award from the American Medical Association for fulfilling the requirements for this award in Continuing Medical Education.

 

1980 - 1983

Monetary scholarship from the Papadakis Foundation, having passed nationwide examinations for university students with the highest score

 

1978 - 1983

Annual honorary scholarships during medical school from the Institute of Government Scholarships.

 

Professional Society Memberships:

Fellow of the American College of Physicians-American Society of Internal Medicine

Fellow of the American College of Cardiology

Member of the National Lipid Association

Member of the American Society of Nuclear Cardiology

Member of the American Medical Association

Member of the Athens Medical Association (Greece)

 

Lectures-Presentations:

Chest Pain in the Hospital

American College of Physicians Internal Medicine 2014 Conference
Orange County Convention Center, Orlando, Florida (4/11/2014).

New Lipid Lowering Drugs on the Horizon

Lecture given as part of a Scientific Symposium entitled ?Hot Topics in Cardiology: ACC Highlights for the Interventional, Invasive, and General Cardiologist? ? Session II: ?Focus on Prevention?.
Transcatheter Cardiovascular Therapeutics Conference-2013 (TCT 2013)
The Moscone Center, San Francisco, California (10/27/2013).

HDL Functionality: An Emerging Concept in Clinical Lipidology

Cardiology Grand Rounds
Westchester Medical Center, Valhalla, New York (10/15/2013).

Friday AM Emory University Cardiology Conference
Emory University Hospital, Atlanta, Georgia (11/16/2012).

Cardiology Fellows? Conference
Mount Sinai Medical Center, New York, New York (10/3/2012).

Omega-3 Fatty Acids in Cardiovascular Disease

Grand Rounds
St. Francis Hospital, Roslyn, New York (12/19/2012).

Lipid Regulating Drug Pharmacology and New Frontiers in the Management of Lipid Disorders Grand Rounds
Mount Sinai Hospital of Queens, Astoria, New York (12/12/2011).

Lecture given as part of a Medical Program entitled ?Hippocrates? Seminars - The Future of Medicine: New Paradigms in Patient Care? and sponsored by the Hellenic Medical Society of Philadelphia in conjunction with the Hellenic Medical Society of New York.
Atlantic City, New Jersey (4/2/2011).

Current Trends in Management of Lipid Disorders

Lecture given as part of a Medical Program entitled ?New Frontiers in the Treatment of Cardiovascular Disorders? and sponsored by an Educational Grant from Biotronik, Inc.
Astoria, New York (11/15/2011).
 

 

Lectures-Presentations (Cont.):

Hypertrophic Cardiomyopathy: From Epidemiology to Electrophysiology

Medical Program sponsored by an Educational Grant from Boston Scientific Corporation.
Astoria, New York (3/17/2010).

Lipid Regulating Drug Pharmacology and Current Trends in the Management of Lipid Disorders

Grand Rounds
St. Barnabas Hospital, Bronx, New York (2/4/2010).

Long QT Syndrome ? Case Presentation Lecture given as part of a Medical Program entitled ?Current Topics in Sudden Cardiac Arrest? and sponsored by an Educational Grant from Medtronic, Inc.
Astoria, New York (11/10/2009).

Statin Pharmacology and Current Trends in Management of Lipid Disorders

Lecture given as part of a Medical Program entitled ?From Preventive Cardiology to Cardiovascular Surgery: Current Trends in Management and New Perspectives? and sponsored by an Educational Grant from Medtronic, Inc.and by an Educational Grant from Terumo Cardiovascular Systems Corporation.
Astoria, New York (2/24/2009).

Hypertrophic Cardiomyopathy and Long QT Syndrome

Lecture given as part of a Medical Program entitled ?Beyond Coronary Artery Disease: Inherited Causes of Sudden Cardiac Death? and sponsored by the Sudden Cardiac Arrest Association and by an Educational Grant from St. Jude Medical, Inc.
Astoria, New York (1/14/2009).

Lipid Regulating Drug Pharmacology and Current Concepts in the Management of Lipid Disorders

Cardiology Conference at the Cardiac Arrhythmia Center
New YorkHospital Queens, Flushing, New York (3/31/2008).

Medicine/Cardiology Conference
New YorkHospital Queens, Flushing, New York (3/12/2008).

Lipid Regulating Drug Pharmacology

Cardiology Core Lecture Series
New York Hospital Queens, Flushing, New York (10/11/2007).

 

Lectures-Presentations (Cont.):

An Update on the Prevention of Sudden Cardiac Death

Medical Program sponsored by an Educational Grant from St. Jude Medical, Inc.
Astoria, New York (11/1/2006).

The Evaluation and Immediate Management of Chest Pain/Acute Myocardial Infarction

2005 Summer Noontime Lecture Series
Department of Medicine
New YorkHospital Queens, Flushing, New York (7/15/2005).

Unstable Coronary Syndrome and Acute Myocardial Infarction

Comprehensive Review of Internal Medicine 2002-2003
New YorkHospital Queens, Flushing, New York (10/11/2002).

Comprehensive Review of Internal Medicine 2001-2002
New YorkHospital Queens, Flushing, New York (10/12/2001).

Acute Myocardial Infarction

2002 Summer Noontime Lecture Series
Department of Medicine
New YorkHospital Queens, Flushing, New York (7/22/2002).

Evidence-based management of hyperlipidemia

Grand Rounds
Family Practice Residency Program
St. John?s Episcopal Hospital, South Shore, Far Rockaway, New York (11/6/2001).

Management of Heart Failure

Comprehensive Review of Internal Medicine 2000-2001
New YorkHospital Queens, Flushing, New York (10/30/2000).

Beta-blockade in the management of heart failure

Cardiology Conference
PennsylvaniaHospital, Philadelphia, Pennsylvania (2/9/2000).

New frontiers in the management of heart failure

Cardiology Conference
PennsylvaniaHospital, Philadelphia, Pennsylvania (4/14/1999).

Mitral valve prolapse and ventricular arrhythmias

Cardiology Conference
PennsylvaniaHospital, Philadelphia, Pennsylvania (3/11/1998).

 

Lectures-Presentations(Cont.):

Medical advances in the treatment of congestive heart failure: Progress through clinical trials

Grand Rounds
St. Joseph?s Hospital/NPHS, Philadelphia, Pennsylvania (5/22/1997).

Cardiology Conference
PennsylvaniaHospital, Philadelphia, Pennsylvania (1/22/1997).

Monthly In-Service Meeting
CAMcare Health Corporation-Camcare Central, Camden, New Jersey (7/8/1996).

Nuclear Cardiology Case Presentation: Normal Thallium imaging in the presence of severe and extensive coronary artery disease

Cardiology Update Symposium: New Frontiers in Cardiology-1997
Four Seasons Hotel, Philadelphia, Pennsylvania (5/3/1997).

Anticoagulation in unstable angina and acute myocardial infarction

Family Practice Meeting
Philadelphia Marriott Hotel, Philadelphia, Pennsylvania (9/13/1995).

 

Participation in Scientific Meetings:

American College of Physicians Internal Medicine 2014 Conference
Orange County Convention Center, Orlando, Florida (4/11/2014).
Faculty (Lecturer)

Transcatheter Cardiovascular Therapeutics Conference-2013 (TCT 2013)
The Moscone Center, San Francisco, California (10/27/2013).
?Hot Topics in Cardiology: ACC Highlights for the Interventional, Invasive, and General Cardiologist? ? Session II: ?Focus on Prevention?
Faculty (Lecturer), Moderator and Discussant

Cardiology Update Symposium: New Frontiers in Cardiology-2000
The Westin Hotel, Philadelphia, Pennsylvania (4/29/2000).
Faculty, Moderator and Member of Discussion Panel

Cardiology Update Symposium: New Frontiers in Cardiology-1998
Four Seasons Hotel, Philadelphia, Pennsylvania (10/10/1998).
Faculty, Moderator and Member of Discussion Panel

Cardiology Update Symposium: New Frontiers in Cardiology-1997
Four Seasons Hotel, Philadelphia, Pennsylvania (5/3/1997).
Faculty

Current Trends in Cardiology-1996: Advances in the Diagnosis and Treatment of Cardiovascular Disease
Four Seasons Hotel, Philadelphia, Pennsylvania (3/30/1996).
Co-Director, Faculty and Member of Discussion Panel

 

Peer Reviews:

2015 - Present

Reviewer of medical manuscripts for the medical journal ?Clinical Medicine Reviews in Cardiology?.

 

2014 - Present

Reviewer of medical manuscripts for the medical journal ?Enliven: Clinical Cardiology and Research?.

 

2014 - Present

Reviewer of medical manuscripts for the medical journal ?International Journal of Cardiology and Cardiovascular Research?.

 

2014

Reviewer of Abstracts for the Transcatheter Cardiovascular Therapeutics Conference-2014 (TCT 2014).

 

2014

Peer reviewer for Elsevier's InOrder? order sets on the topic of ?Cardiac Arrest Hypothermia Protocol?.

 

2013

Peer reviewer for Elsevier's InOrder? order sets on the topic of ?Dyslipidemia?

 

2013

Peer reviewer for Elsevier's InOrder? order sets on the topic of ?Advanced Cardiac Life Support (ACLS)?.

 

2013

Peer reviewer for Elsevier's InOrder? order sets on the topic of ?Acute Coronary Syndrome?.

 

Editorial Board of Medical Journals:

2014 - Present

Enliven: Clinical Cardiology and Research

 

Bibliography

Original Articles:

Choi KJ, Tsomidou C, Lerakis S, Madanieh R, Vittorio TJ, Kosmas CE: Lipid interventions in aortic valvular disease.
Am J Med Sci (In press).

Kosmas CE,DeJesus E: Proprotein convertase subtilisin/kexin type 9 inhibitors: an emerging chapter in the field of clinical lipidology.
Enliven:ClinCardiol Res (In press).

Patel H, Madanieh R, Kosmas CE, Vatti SK, Vittorio TJ: Reversible cardiomyopathies.
Clin Med Insights Cardiol 2015;9(Suppl 2):7-14.

Patel H, MadaniehR,Kosmas CE, Vatti SK, Vittorio TJ: Complications of continuous-flow mechanical circulatory support devices.
Clin Med Insights Cardiol2015;9(Suppl 2):15-21.

Kosmas CE,Frishman WH: New and emerging LDL cholesterol-lowering drugs.
Am J Ther2015;22(3):234-241.

Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE: Inflammation in coronary artery disease.
Cardiol Rev 2014;22(6):279-288.

Kosmas CE,Christodoulidis G, Cheng JW, Vittorio TJ, Lerakis S: High-density lipoprotein functionality in coronary artery disease.
Am J Med Sci 2014;347(6):504-508.

Vittorio TJ, Fudim M,Wagman G,Kosmas CE: Alpha-1 adrenoceptor-angiotensin II type 1receptor cross-talk and its relevance in clinical medicine.
Cardiol Rev 2014;22(2):51-55.

Akhabue E, ThiboutotJ, Cheng JW, Vittorio TJ,Christodoulidis G, Grady KM,Lerakis S,Kosmas CE: New and emerging risk factors for coronary heart disease.
Am J Med Sci 2014;347(2):151-158.

 

Bibliography

Original Articles (Cont.):

Kosmas CE,Alkhawam H, El-Hunjul M, Wagman G, Kahn MR, Grady KM, Vittorio TJ: Statin-mediated low-density lipoprotein lowering in chronic congestive heart failure.
Am J Med Sci 2014;347(1):14-22.

Mathew S, Kosmas CE, Siegel RR, Vittorio TJ: Toxicity of abdominal fat.
Health 2013;5(8A3):96-99.

SavinoJA 3rd, Kosmas CE,Wagman G, Vittorio TJ: Evolution of the chronic congestive heart failure paradigm.
Cardiol Rev 2013;21(3):121-126.

Kahn MR,Kosmas CE, Wagman G, Serrao GW, Fallahi A, Grady KM, Vittorio TJ: Low-density lipoprotein levels in patients with acute heart failure.
Congest Heart Fail 2013;19(2):85-91.

Kosmas CE, TsomidouCh, Lerakis, S: C-reactive protein,lipoprotein (a),homocysteineand lipoprotein-associatedphospholipase A2as risk factors for coronaryheart disease.
Iatriki 2012;101(6):395-400. [In Greek with English summary].

Dangas G, O?Connor D, Firwana B, Brar S, Ellozy S, Vouyouka A, Arnold M, Kosmas CE, Krishnan P, Wiley J, Suleman J, Olin J, Marin M, Faries P: Open versus endovascular stent graft repair of abdominal aortic aneurysms: a meta-analysis of randomized trials.
JACC CardiovascInterv 2012;5(10):1071-1080.

Lanier GM,Vaishnava P, Kosmas CE, Wagman G, Heinsch R, Vittorio TJ: An update on diastolic dysfunction.
Cardiol Rev 2012;20(5):230-236.

Wagman G, Fudim M, Kosmas CE, Panni RE, Vittorio TJ: The neurohormonal network in the RAAS can bend before breaking.
Curr Heart Fail Rep 2012;9(2):81-91.

Kosmas CE, Skliros D, TsomidouCh: The role of omega-3 fatty acids in cardiovascular disease.
Iatriki 2012;101(1):16-27. [In Greek with English summary].

Kosmas CE, Philippou C: HDL functionality: a new chapter in the field of clinical lipidology.
Iatriki 2011;100(5-6):247-252. [In Greek with English summary].

Charitos C, Nanas JN, Nanas SN, Chatzigeorgiou I, Alevizakos N, Cosmas K, Moulopoulos SD: Right and left ventricular interaction in ventricular fibrillation with mechanical maintenance of the circulation.
J CardiovascSurg (Torino) 1998;39(3):363-366.
 

 

Bibliography

Original Articles (Cont.):

Kosmas CE, Mallozzi M, Moten M, Banka VS: Clinical symptomatology of coronary artery disease and results of exercise thallium scintigraphy: gender-related differences.
Indian Heart J 1997;49(5):497-501.

Kosmas CE, Ryder RG, Poon MJ, Zelenkofske SL, Banka VS: Time-limited efficacy of pacing electrodes following open heart surgery.
Indian Heart J 1996;48(6):681-684.

Kosmas CE, Dalessandro DA, Langieri G, Rubin AM, Rials SJ, Marinchak RA, Kowey PR: Monomorphic right ventricular tachycardia in a patient with mitral valve prolapse.
Pacing ClinElectrophysiol 1996;19(4 Pt I):509-513.

Kosmas CE,Mazuz M, Rubin AM, Marinchak RA, Kowey PR: Wide complex tachycardia in a man with coronary artery disease.
Choices in Cardiology 1995;9(1):15.

Kosmas CE, Rubin AM, Rials SJ, Marinchak RA, Kowey PR: Abnormal rhythm strip in a man with heart failure and ventricular tachycardia.
Choices in Cardiology 1994;8(7):205.

Nanas JN, Charitos C, Poyiadjis A, Anastasiou-Nana M, Cosmas C, Alevizakos N, Laoutidis G, Moulopoulos S: Maintenance of circulation during ventricular fibrillation with the simultaneous use of two ?counterpulsation? devices.
ASAIO Trans 1990;36(3):M395-M397.

Poyiadjis A, Nanas J, Nanas S, Charitos C, Kontoyiannis D, Melkaoui A, Cosmas C, Moulopoulos SD: Hemodynamic effects of the simultaneous use of para-aortic counterpulsation device and intra-aortic balloon pump in graded heart failure.
Hell Cardiol Rev (Athens) 1990;31:18-25. [In Greek with English summary].

 

Bibliography

Book Contributions:

Kosmas CE: Contributor in ?Kosmas CE: Contributor in ?Reviewofobesityandbariatricsurgery: Essential notes and multiple choice questions?, Kini S and Rao R (eds.). London, New York: Informa Healthcare, 2012.

Kosmas CE, Banka VS: Non-surgical coronary revascularization: Evolution of catheter-based techniques and role of the plain-old balloon angioplasty.InMunjal YP (ed.): Medicine Update 1997. New Delhi, The Association of Physicians of India, 1997:98-107.

 

Bibliography

Abstracts:

Kosmas CE, Mallozzi M, Moten M, Banka VS: Clinical symptomatology of coronary artery disease is less predictive of a positive exercise thallium test in women than in men.
J Investig Med 1996;44(3):285A.

Banka VS, Kosmas CE, Sharma V: Additive antiproliferative effects of calcium channel antagonist, HMG Coenzyme A reductase inhibitor and angiotensin converting enzyme inhibitor on human coronary smooth muscle cells.
J Investig Med 1996;44(3):315A.

Sharma V, Kosmas CE, Banka VS: Anti-proliferative effect of simvastatin on human coronary smooth muscle cells: comparison with lovastatin.
Circulation 1995;92(suppl I):I-18.

Kosmas CE, Mallozzi M, Banka VS, Moten M: Clinical symptomatology is less predictive of coronary artery disease in women than in men.
J Investig Med 1995;43(supplII):405A.

Kosmas CE, Ryder RG, Poon MJ, Banka VS, Zelenkofske SL: Usefulness of pacing electrodes following open heart surgery.
2ndScientificConferenceoftheAssociationofCardiovascularSurgeonsofUkraine,Kiev,1994, page 172.

Nanas J, Charitos C, Poyiadjis A, Nanas S, Kontoyiannis D, Cosmas C, Moulopoulos S: Maintenance of circulation during ventricular fibrillation with the simultaneous use of two ?counterpulsation? devices.
American Society for Artificial Internal Organs, 36th Annual Meeting, Washington, D.C., 1990, Page 52.

Nanas J, Poyiadjis A, Kontoyiannis D, Melkaoui A, Stamatopoulos G, Charitos C, Nanas S, Cosmas C, Moulopoulos S: Hemodynamiceffects of the simultaneous use of two counterpulsation pumps in various stages of heart failure.
10th Panhellenic Cardiology Conference, Athens, 1988, page 63. [In Greek].

 

Alternative Media

Internet:

1997 ? 2001

Member of the Expert Panel in Cardiovascular Disease at the Pharmaceutical Information Network (http://www.pharminfo.com)

 

  • The Pharmaceutical Information Network was a healthcare website with a mission to improve healthcare by delivering products and services that provided reliable digital clinical data and up-to-date information to healthcare professionals and consumers. Expert panels from different medical specialties participated in on-line clinical discussions with other medical professionals and answered on-line medical questions from patients all over the world.


Telivision

2011 ? 2014

Host of the Medical Program?HealthConcerns?, sponsored by the Mount Sinai Medical Center on the 24-hour National Greek Television Channel (NGTV-Channel 545) in New York

 

  • The Medical Program ?Health Concerns?, sponsored by the Mount Sinai Medical Center,included discussions with experts from different medical specialties regarding topics of interest within their area of expertise. The experts also answered live call-in questions from the television audience. [In Greek].


2008 ? 2010

Host of the Medical Program?Hippocrates? Forum?, sponsored by the Cardiovascular Group ?Cardiovascular Associates of New York? and the Lenox Hill Hospital on the 24-hour National Greek Television Channel (NGTV-Channel 545) in New York?Hippocrates? Forum?, sponsored by the Cardiovascular Group ?Cardiovascular Associates of New York? and the Lenox Hill Hospital on the 24-hour National Greek Television Channel (NGTV-Channel 545) in New York

 

  • The Medical Program ?Hippocrates? Forum?, sponsored by the Cardiovascular Group ?Cardiovascular Associates of New York? and the Lenox Hill Hospital,included discussions with experts from different medical specialties regarding topics of interest within their area of expertise. The experts also answered live call-in questions from the television audience. [In Greek].


Alternative Media

Television(cont.):

2004 ? 2008

Host of the Medical Program, sponsored by the KyreniaCardiovascularCenter and the New York Hospital Queens on the 24-hour National Greek Television Channel (NGTV-Channel 545) in New York

 

  • The Medical Program, sponsored by the Kyrenia Cardiovascular Center and the New York Hospital Queens, included discussions with experts from different medical specialties regarding topics of interest within their area of expertise. The experts also answered live call-in questions from the television audience. [In Greek].

 

2000 ? 2002

Guest Specialist in Cardiovascular Disease on the Medical Program, sponsored by the Kyrenia Cardiovascular Center and the New York Hospital Queens on the 24-hour National Greek Television Channel (NGTV-Channel 545) in New York

 

Cardiovascular topics included:

3/27/2002

Heart Murmurs

1/16/2002

Syncope

11/14/2001

Acute Myocardial Infarction

10/24/2001

Hypercholesterolemia

6/20/2001

Cardiac Pacemakers

5/16/2001

Valvular Heart Disease - Cardiac Arrhythmias - Hypertension

2/28/2001

Management of patients with acute myocardial infarction after discharge from the hospital

12/27/2000

Effect of extreme weather conditions on patients with coronary artery disease

11/15/2000

Endocarditis - Pericarditis

10/18/2000

Atrial Fibrillation

10/11/2000

Heart Failure

9/13/2000

Coronary Artery Disease - Cardiac Arrhythmias

 

Alternative Media

Television(cont.):

  • The medical program ?Correct Motion-Better Health?, sponsored by the physical therapists Dimitrios Kostopoulos, PT, PhD and KonstantineRizopoulos, PT, FABS and the organization Hands-On Physical Therapy, PC, included discussions with experts from related medical specialties regarding topics of interest within their area of expertise. The experts also answered call-in questions from the television audience. [In Greek].


 

Subject: Coronary Artery Disease

 

Radio:

5/3/2014

Guest Specialist in Cardiovascular Disease on the medical program ?Health and Life? on the Greek-American radio station COSMOS FM (WNYE 91.5 FM - New York)

 

  • The medical radio program ?Health and Life? is an informative series on various medical issues. In addition, medical news are presented and medical advice is given by experts from different medical specialties. [In Greek].


 

Subject: The significance of HDL Cholesterol

 

2/26/2011 and 3/7/2009

Guest Specialist in Cardiovascular Disease on the medical program ?Health and Life? on the Greek-American radio station COSMOS FM (WNYE 91.5 FM - New York)

 

 

Subject: Coronary Artery Disease

 

9/23/2000

Guest Specialist in Cardiovascular Disease on the medical program ?Praise of Health? on the bilingual Greek-American radio station AKTINA FM (WNYE 91.5 FM - New York)

 

  • The medical radio program ?Praise of Health? was an informative series on various medical issues. Experts from different medical specialties discussed topics of interest within their area of expertise and answered live call-in questions from the radio audience. [In Greek and English].


 

Subject: Coronary Artery Disease

 

Alternative Media

Newspapers-Magazines:

2012 ? 2013

Regular contributor to the medical column ?Health Tribune?in the ?Magazine? of the Greek-American newspaper ?The National Herald?. [In Greek].

 

2/2002

Article entitled ?Coronary artery disease - Etiology, symptoms and treatment? in ?Eseis?, a Greek-American magazine. [In Greek].

 

11/11-12/2000

Article entitled ?What is coronary artery disease? in ?Proini?, an Independent Greek-American daily newspaper. [In Greek].
Information of Article
Download Pdf